FORA Capital LLC Makes New Investment in Repligen Co. (NASDAQ:RGEN)

FORA Capital LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,413 shares of the biotechnology company’s stock, valued at approximately $203,000.

Other large investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its position in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 90 shares during the last quarter. Clark & Stuart Inc bought a new position in shares of Repligen in the 4th quarter worth approximately $202,000. Moody National Bank Trust Division boosted its holdings in shares of Repligen by 10.2% in the fourth quarter. Moody National Bank Trust Division now owns 1,591 shares of the biotechnology company’s stock worth $229,000 after buying an additional 147 shares during the last quarter. Park Avenue Securities LLC grew its position in Repligen by 24.8% during the fourth quarter. Park Avenue Securities LLC now owns 3,901 shares of the biotechnology company’s stock valued at $561,000 after buying an additional 776 shares during the period. Finally, Integrated Investment Consultants LLC increased its holdings in Repligen by 6.0% during the fourth quarter. Integrated Investment Consultants LLC now owns 2,360 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 134 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Thursday. Canaccord Genuity Group cut their target price on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research report on Wednesday, April 16th. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a report on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Stock Down 3.6 %

Repligen stock opened at $123.24 on Friday. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock’s 50 day moving average price is $135.03 and its 200 day moving average price is $145.37. The company has a market cap of $6.92 billion, a PE ratio of -241.65, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the company posted $0.28 EPS. On average, sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Activity

In related news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.